Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neurofibromatosis 1 5Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Neurofibroma, Plexiform 2Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Optic Nerve Glioma 1Neurofibrosarcoma 1Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Astrocytoma 1Acquired Immunodeficiency Syndrome 1AIDS-related Kaposi sarcoma 1

Interventions

Temozolomide 12Bevacizumab 8Carboplatin 6Radiotherapy 5Erlotinib Hydrochloride 5temsirolimus 3Surgical Procedures, Operative 3Irinotecan 3IL13-PE38 3veliparib 2pembrolizumab 2etoposide phosphate 2Vorinostat 2Specimen Handling 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiotherapy, Conformal 2Radiation 2Magnetic Resonance Spectroscopy 2Imatinib Mesylate 2Genetic Therapy 2Everolimus 2Cetuximab 2Carmustine 2Cancer Vaccines 2trastuzumab deruxtecan 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1terameprocol 1sonidegib 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Astrocytoma × AZD 6244 × Clear all
NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
217 enrolled
CNS

Astrocytoma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡